Evogene price target lowered to $1.75 from $2.50 at Alliance Global

Alliance Global lowered the firm’s price target on Evogene (EVGN) to $1.75 from $2.50 and keeps a Buy rating on the shares. Evogene reported Q4 earnings that were within the range of expectations, the analyst tells investors in a research note. The firm said the main points include: the company’s focus is on the ChemPass AI discovery engine; the company has already reached four collaborations and more are expected; the firm expects molecules to enter preclinical testing in 1H27, and; the cash balance appears to extend into 2H27.